International journal of geriatric psychiatry
-
Int J Geriatr Psychiatry · Dec 2011
Randomized Controlled Trial Multicenter StudyRivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
The cholinesterase inhibitor rivastigmine is approved for the symptomatic treatment of mild to moderate Alzheimer's disease (AD). This exploratory, hypothesis-forming analysis assessed response to rivastigmine according to severity of dementia at baseline. ⋯ Rivastigmine benefits AD patients across dementia stages. Similar to previous cholinesterase inhibitor studies, greatest treatment effects with rivastigmine patch and capsule were seen in patients with more advanced dementia, most likely driven by greater placebo decline in this population.